SMOFlipid® (lipid emulsion – Fresenius Kabi) has received an expanded indication as a source of calories and essential fatty acids in patients of all ages receiving parenteral nutrition when oral or enteral nutrition is insufficient, not possible, or contraindicated. Previously, the product was approved only for adults.

• Parenteral nutrition describes intravenous administration of nutritional products, while enteral nutrition is the delivery of nutritional products through the gastrointestinal (GI) tract, such as via a gastrointestinal (GI) tube.
• Recommended SMOFlipid dosing is based on the patient’s age, energy expenditure, clinical status, body weight, tolerance, ability to metabolize and eliminate lipids, and consideration of additional energy given to the patient. Infusion times can range from 12-24 hours.
• SMOFlipid first received FDA approval in 2016.